Want to see DE:EVT full AI Analyst Report?
EVT Stock Chart & Stats
€3.45
€0.03(0.75%)
At close: 4:00 PM EDT
€3.45
€0.03(0.75%)
Day’s Range― - ―
52-Week Range€3.18 - €7.30
Previous CloseN/A
Volume239.44K
Average Volume (3M)812.37K
Market Cap
€604.75M
Enterprise Value€898.74
Total Cash (Recent Filing)€465.59M
Total Debt (Recent Filing)€475.87M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 05, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding177,909,560
10 Day Avg. Volume1,027,144
30 Day Avg. Volume812,370
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.19
Price to Sales (P/S)1.23
P/FCF Ratio-11.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.03Price Target Upside74.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.17
Revenue Forecast (FY)€601.05M
Bulls Say, Bears Say
Bulls Say
Business RecoveryPotential upside exists upon business recovery and as focus assets shift to later stages of development.
Debt ManagementDespite the net debt leverage ratio reaching 4.3x, management remains confident about meeting upcoming covenants.
Bears Say
Financial PerformanceThe net debt leverage ratio reached 4.3x, partly due to worsening EBITDA, indicating additional net debt reduction is needed.
Market UncertaintyThere is uncertainty over the timing of clarity on Evotec's 2025+ trajectory, with a risk that no guidance will be provided soon.
Evotec News
EVT FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest stock price was €3.18 and its highest was €7.30 in the past 12 months.
What is Evotec’s market cap?
Evotec’s market cap is €604.75M.
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is Nov 05, 2026 which is in 75 days.
How were Evotec’s earnings last quarter?
Evotec released its earnings results on Aug 13, 2026. The company reported -€0.26 earnings per share for the quarter, missing the consensus estimate of -€0.07 by -€0.19.
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate is -0.47.
How many shares outstanding does Evotec have?
Evotec has 177,909,560 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Evotec reported an EPS of -€0.26 in its last earnings report, missing expectations of -€0.07. Following the earnings report the stock price went down -7.844%.
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in DE:EVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.03 (74.88% Upside)
€6.03 (74.88% Upside)
Insider Transactions
Sold Shares
Worth €636.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Evotec
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
EVT Stock 12 Month Forecast
Average Price Target
€6.03
▲(74.88% Upside)
Technical Analysis
Biofrontera
―
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Merck KGaA
―
Heidelberg Pharma AG
―